Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 plus pembrolizumab in selected solid tumors
2022-502654-14-00Phase 2Authorised
- Sponsor
- Kelun-Biotech
- Start
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and pembrolizumab in endometrial cancer (EC), Cervical Cancer (CC), prostate cancer (PCa) and 2 more, sponsored by Kelun-Biotech. Primary endpoints: Number of subjects with dose-limiting toxicities, Number of subjects with adverse events and 3 more. Planned start Sep 2023; status: authorised.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
endometrial cancer (EC)Cervical Cancer (CC)prostate cancer (PCa)transitional cell carcinoma (TCC)ovarian cancer
Beyond the preview
Go deeper on 2022-502654-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502654-14-00.